Medicines and preparations of unknown origin used illegally for pharmacological abortive purposes

Authors

  • Adam Mazurek Z Narodowego Instytutu Leków
  • Piotr Baran Z Narodowego Instytutu Leków
  • Agata Błażewicz Z Narodowego Instytutu Leków
  • Paweł Januszewicz Z Narodowego Instytutu Leków; Z Wydziału Pielęgniarstwa i Nauk o Zdrowiu Uniwersytetu Rzeszowskiego
  • Krzysztof Jop Z Narodowego Instytutu Leków
  • Jan Maurin Z Narodowego Instytutu Leków; Z Instytutu Energii Atomowej – Polatom

Keywords:

medical abortion, pharmacology, forensic study, identification

Abstract

The paper comprises the discussion of forensic studies results obtained in National Medicines Institute in 2007–2011 period of preparations in a form of tablets and capsules secured by the police and prosecution in connection with illegal abortions. The literature overview on legal an illegal medical abortion in Poland and selected countries in the world has been supplied. A qualitative analysis of these products was performed by means of instrumental methods. Preparations contained the following active ingredients: misoprostol (Cytotec, Misoprostol 200 μg), misoprostol and diklofenac (Arthrotec), mifepristone (Mifepristone Tablets 200 mg), prednisone (Encorton), acetylsalicic acid, methotrexate. Also capsules with omeprazole were studied. Preparations with misoprostol or omeprazole are used in stomach and duodenum inflammatory conditions whereas those with misoprostol and diclofenac in joints inflammatory and degradation conditions treatment. The use of such medicinal products for abortion is in Poland illegal and their action is based on undesirable side effects reported for upper mentioned therapies. Encorton containing prednisone does not cause miscarriages but its use during pregnancy can be involved in infants’ adrenal gland deficiencies. During some experts reports preparations it was found that the preparations offered on the market consist of pure lactose and do not contain any active ingredient.

Downloads

Download data is not yet available.

References

Ustawa o planowaniu rodziny, ochronie płodu ludzkiego i warunkach dopuszczalności przerywania ciąży. 1993 Dz. U. Nr 17, poz.78 ze zmianami.

Sygn. akt K 26/96 – Orzecznictwo Trybunału Konstytucyjnego rok 1997, Nr 2, poz. 19.

Ustawa o planowaniu rodziny, ochronie płodu ludzkiego i warunkach dopuszczalności przerywania ciąży. 1993 Dz. U. Nr 17, poz.78 ze zmianami, art. 4a ust. 1 pkt. 4.

Ustawa o planowaniu rodziny, ochronie płodu ludzkiego i warunkach dopuszczalności przerywania ciąży. 1993 Dz. U. Nr 17, poz.78 ze zmianami, art. 4a ust. 1 pkt 1-3,

Sprawozdanie Rady Ministrów z wykonywania oraz o skutkach stosowania w roku 2009 ustawy z dnia 7 stycznia 1993 r. o planowaniu rodziny, ochronie płodu ludzkiego i warunkach dopuszczalności przerywania ciąży. Druk nr 3724, Sejm RP Warszawa, 14 grudnia 2010 r. 55-61.

Prawa reprodukcyjne w Polsce, skutki ustawy antyaborcyjnej, Nowicka W. ( red.), Raport, Wydawca: Federacja na rzecz Kobiet i Planowania Rodziny ul. Nowolipie 13/15, 00-150 Warszawa, wrzesień 2007, 1-103.

Grimes D. A., Unsafe abortion: the silent scourge, British Medical Bulletin 2003, 67, 99-113.

Kodeks karny Dz. U. 1997.88.553, art. 152 § 1 i 2.

Kodeks karny Dz. U. 1997.88.553, art. 152 § 3.

Kodeks karny Dz. U. 1997.88.553, art. 154.

Kodeks karny Dz. U. 1997.88.553, art. 157a.

Kodeks cywilny Dz. U. 1964.16.93, art. 4461 .

Kodeks cywilny Dz. U. 1964.16.93, art. 444.

Kodeks cywilny Dz. U. 1964.16.93, art. 446.

Mesce D., Clifton D., Abortion, Facts & Figures, Population Reference Bureau, Washington, www. prb.org (04.2011).

Tang O.S., Gemzell-Danielsson K., Ho P.C., Misoprostol: Pharmacokinetics, profiles, effects on the uterus and side-effects. International Journal of Gynecology and Obsterics, 2007, 99, 16-167.

Niimäki M., Medical compared with surgical management induced abortions and miscarriages, Acta Universitas Ouluensis, D Medica 1032, 2009, 1-91.

Ipas, Medical Abortion Study Guide, Ipas, Chapel Hill N.C. 2009, 1-85.

Patel L., Bennett T.A., Halpern C.T., Johnston H.B. Suchindran Ch.M., Support for provisions of early medical abortion by mid-level providers in Bihar and Jharkhand, India, Reproductive Health Matters, 2009, 17(33) 70-79.

Banfi R., Pavone E., Cerri R., Menichetti M., Mifepristone in Italy: the case of drug trapped between ethics and clinical practice. Pharm World Sci 2007, 29, 400-403.

Szymańska M., Knapp P., Opinions of gyneacologists on prenatal diagnostics in first/second trimester and abortion – ethical aspect. Advantages in Medical Science, 2007, 52, 182-185.

Blum J., Swica Y., Proposal for the inclusion of misoprostol in the WHO list of essential medicines, WHO, 17th Expert Committee on the Selection and Use of Essential Medicines, Geneva, March 2009, 1-20.

Antommattei O., Khanfar N.M., Mujtaba B.G., Global Abortion and Marketing Challenges for Misoprostol (Cytotec), Future of Women’s Health, International Business & Economic Research Journal, January 2009, 8, 1, 105-112.

Klimek-Wierzbicka P., Czarny rynek mizoprostolu, Manager apteki, 10.10.2010, 8-9.

Mazanek-Mościcka M., Brożek J., Skuteczność mizoprostolu podanego dopochwowo w porównaniu z aspiracją zawartości jamy macicy w przypadku niepowodzenia ciąży w I trymestrze, Opracowanie w internetowym portalu dla lekarzy Medycyna Praktyczna, http://www.mp.pl, (21.04.2008).

Watoła J., Aborcja tabletkami na wrzody, Gazeta Wyborcza 21.04.2011, 5.

Downloads

Published

2012-06-30

How to Cite

Mazurek, A., Baran, P., Błażewicz, A., Januszewicz, P., Jop, K., & Maurin, J. (2012). Medicines and preparations of unknown origin used illegally for pharmacological abortive purposes. European Journal of Clinical and Experimental Medicine, 10(2), 238–244. Retrieved from https://journals.ur.edu.pl/ejcem/article/view/12768

Issue

Vol. 10 No. 2 (2012): Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

Section

REVIEW PAPERS

License

Copyright (c) 2012 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.